This article is more than 5 years old. Information may no longer be current.

MacuSight begins phase 1 study of liquid sirolimus treatment for wet AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

UNION CITY, Calif. — MacuSight Inc. has initiated a phase 1 study of its proprietary liquid formulation of sirolimus for treating age-related macular degeneration, the company announced.

In September, MacuSight initiated a phase 1 study of the same sirolimus formulation for the treatment of diabetic macular edema. The new randomized study will include 30 patients at six centers, evaluating the safety and tolerability of both subconjunctival and intravitreal injections of three sirolimus doses. Each injection will expose the study participants to the drug for up to 3 months, according to a press release.

Sirolimus is an immunosuppressant drug with antiangiogenic, antiproliferative and antimigratory activity. MacuSight officials believe the drug's broad range of activity may make it useful as both a front-line and a preventive treatment for both wet AMD and diabetic macular edema, according to the release.